Please try another search
For the three months ended 31 March 2022, Genome&Company revenues increased from W141.4M to W2.75B. Net loss increased 29% to W9.46B. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Salaries & Wages increase of 91% to W1.41B (expense), Commission Paid increase of 65% to W637.7M (expense).
Period Ending: | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 |
---|---|---|---|---|
Total Revenue | 3578.39 | 4457.73 | 3713.88 | 2546 |
Gross Profit | 957.47 | 1657.78 | 994.62 | 454.04 |
Operating Income | -20213.24 | -10538.99 | -11889.39 | -12450.74 |
Net Income | -22342.15 | -9005.52 | -5853.75 | -10264.33 |
Period Ending: | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 |
---|---|---|---|---|
Total Assets | 162060.39 | 180531 | 176942.63 | 163739.96 |
Total Liabilities | 48543.27 | 49541.14 | 39197.59 | 20938.73 |
Total Equity | 113517.12 | 130989.85 | 137745.04 | 142801.23 |
Period Ending: | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 |
---|---|---|---|---|
Period Length: | 0 Months | 0 Months | 0 Months | 0 Months |
Cash From Operating Activities | -7224.47 | -6610.76 | -8440 | -9948.73 |
Cash From Investing Activities | -3937.18 | -4018.22 | -16761.85 | 9287.32 |
Cash From Financing Activities | 191.53 | 8494.74 | 22437.36 | -555.54 |
Net Change in Cash | -13442 | -643.54 | -2303.72 | 529.53 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review